• 1
    Onoufriadis A, Simpson MA, Pink AE et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011; 89:4327.
  • 2
    Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:6208.
  • 3
    Körber A, Mössner R, Renner R et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol 2013; 133:26347.
  • 4
    Viguier M, Guigue P, Pagès C et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153:667.
  • 5
    Towne JE, Sims JE. IL-36 in psoriasis. Curr Opin Pharmacol 2012; 12:48690.
  • 6
    Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name? Arch Dermatol 2012; 148:3814.
  • 7
    Zhu KJ, Zhu CY, Fan YM. Alcohol consumption and psoriasis risk: a meta-analysis of case–control studies. J Dermatol 2012; 39:7703.
  • 8
    Towne JE, Renshaw BR, Douangpanya J et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36 β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem 2011; 286:42594602.